References in periodicals archive ?
The elderly comprise an increasing proportion of patients with non-ST-elevation acute coronary syndromes (NSTE-ACS),4 and are more likely to have multivessel disease (MVD) compared with younger patients.
 However, DD in NSTE-ACS (unstable angina and STEMI) has continued to be a gray zone area for a matter of debate.
* When treating patients with ACS, including NSTE-ACS or STEMI, DAPT for 1 year is recommended (SOR: A).
First, although ticagrelor was recommended in patients with STEMI, or with NSTE-ACS at moderate-to-high risk of ischemic events,, patients at low risk of ischemic events might be included in this study because of its nature of real-world study and without specific exclusion criteria.
This pathological characteristic determines that the acute treatment principles of NSTE-ACS and ST-segment elevation myocardial infarction (STEMI) are different.5,6 The near-term death risk in patients with NSTE-ACS is less than that in patients with STEMI, but serious risk of coronary events, such as the medium and long-term mortality, myocardial infarction, is not low.7 It is reported that revascularization can improve the medium and long-term prognosis of patients with NSTE-ACS.
(1) regarding the predictive value of mean platelet volume (MPV) in young patients with non-ST-segment elevation acute coronary syndrome's (NSTE-ACS).
The balance between benefit and hazard in patients treated for NSTE-ACS and STEMI lay in favour of giving three antiplatelet agents (typically aspirin, clopidogrel and an intravenous GPIIb/IIIa receptor antagonist) thereby supporting guidelines promoting this approach.
A study showed that compared with the TIMI score, the GRACE score provides greater diagnostic information with regards to the extent of CAD in patients with NSTE-ACS; and especially for 3VD and multiple rapid progression in nonculprit lesions, the discriminatory accuracy of GRACE score was superior to that of TIMI score.9 The results of our study compare well with the study, suggesting that the GRACE score should be given preference in risk-stratifying NSTE-ACS patients as it is associated both with better assessment of mortality as well as prediction of the severity of CAD.
51.9% of the patients in the tennis group suffered from non-ST segment elevation acute coronary syndrome (NSTE-ACS), 18.5% had acute coronary syndrome with anterior ST segment elevation (STE-ACS) and 29.6% had acute coronary syndrome with inferior ST segment elevation (STE-ACS); the control group (n = 25) was 40% NSTE-ACS, 32% STE-ACS anterior and 28% STE-ACS inferior, and the bicycle ergometer group was 37.1% NSTE-ACS, 22.2% STE-ACS anterior and 40.7% STE-ACS inferior.
The analysis evaluated outcomes in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) managed with or without in-hospital revascularisation in relation to measurements at randomization of high-sensitivity troponin-T (hs-TnT), a biomarker test that may be a more sensitive indicator of ongoing heart muscle damage than previously available troponin tests.
To reduce the risk of adverse ischemic outcomes and death, angioplasty should be done within 24 hours of presentation for non-ST-segment elevation acute coronary syndromes (NSTE-ACS), new research shows.
Acronyms browser ?
Full browser ?
- NSTAR Gas and Electric